Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study.

Saved in:
Bibliographic Details
Title: Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study.
Authors: Susiriwatananont, Thiti1 (AUTHOR), Wongkraisri, Concord2 (AUTHOR), Dajsakdipon, Thanate3 (AUTHOR), Supavavej, Archara4 (AUTHOR), Dechaphunkul, Arunee5 (AUTHOR), Sunpaweravong, Patrapim5 (AUTHOR), Neesanun, Sunee6 (AUTHOR), Ithimakin, Suthinee2 (AUTHOR), Dejthevaporn, Thitiya3 (AUTHOR), Parinyanitikul, Napa1 (AUTHOR) napaparinyanitikul@gmail.com, Tyagi, Abhishek (AUTHOR) atyagi@wakehealth.edu
Source: International Journal of Breast Cancer. 11/4/2025, Vol. 2025, p1-13. 13p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20903170
DOI:10.1155/ijbc/5597051